Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated with Docetaxel
Menée aux Etats-Unis à partir de données d'essais randomisés de phase III portant sur 8 820 patients atteints d'un cancer métastatique de la prostate résistant à la castration et ayant reçu un traitement contenant du docétaxel (âge médian au diagnostic : 69 ans), cette étude analyse la survie chez les hommes en fonction de l'origine ethnique (caucasienne ou asiatique)
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castrate resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel/prednisone (DP) or a DP containing-regimen. Individual participant data from 8,820 men with mCRPC randomized on nine phase III trials to receive DP or DP containing-regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median OS was 18.8 months (95% CI = 17.4-22.1 months) and 21.2 months (95% CI = 20.8-21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84-1.09) indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter overall survival duration than white men treated with docetaxel.
JNCI Cancer Spectrum 2020